Previous studies have shown that the therapeutic effect of arsenic in APL is based on its ability to trigger PML or PML/RARA re-assembly in NBs, hyper-sumoylation and subsequent PML/RARA degradation7,21,31–33. The gene discussed is PML; the disease is acute promyelocytic leukemia.